Week 12 Reduction in Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease is Predictive of Delayed Response to Upadacitinib in Crohn’s Disease
Open Access
- 27 December 2025
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (10) , 2809-2816
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
This publication has 8 references indexed in Scilit:
- Use of Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND TrialJournal of Crohn's and Colitis, 2024
- JAK inhibitors for inflammatory bowel disease: recent advancesFrontline Gastroenterology, 2023
- Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early RespondersClinical Gastroenterology and Hepatology, 2023
- Upadacitinib Induction and Maintenance Therapy for Crohn’s DiseaseNew England Journal of Medicine, 2023
- Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn’s DiseaseJournal of Crohn's and Colitis, 2021
- Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD)Gut, 2021
- Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?World Journal of Gastroenterology, 2017
- Crohn's diseaseThe Lancet, 2012